Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Elahe Karimi-Shahrbabak"'
Autor:
Zahra Yari, Zahra Naser-Nakhaee, Elahe Karimi‐Shahrbabak, Makan Cheraghpour, Mehdi Hedayati, Seyede Marjan Mohaghegh, Shahrzad Ommi, Azita Hekmatdoost
Publikováno v:
Diabetology & Metabolic Syndrome, Vol 13, Iss 1, Pp 1-11 (2021)
Abstract Background Regarding the increasing prevalence of cardiometabolic abnormalities, and its association with non-communicable chronic diseases, providing preventive and therapeutic strategies is a priority. A randomized placebo-controlled study
Externí odkaz:
https://doaj.org/article/1cdb98f23a844097a9b091f82a5aa71e
Autor:
Yamna Ali, Pierre-Philippe Piche-Renaud, Elahe Karimi-Shahrbabak, Daniel S. Farrar, Sarah Abu Fadaleh, Sharon Burey, Shaun K. Morris
Publikováno v:
Vaccine. 41:3058-3065
Autor:
Pierre-Philippe Piché-Renaud, Elahe Karimi-Shahrbabak, Sarah Abu Fadaleh, Daniel Farrar, Julia Orkin, Michelle Science, Shaun Morris
Publikováno v:
Canada Communicable Disease Report. 49:127-132
Autor:
Pierre-Philippe Piché-Renaud, Elahe Karimi-Shahrbabak, Sarah Abu Fadaleh, Daniel Farrar, Julia Orkin, Michelle Science, Shaun Morris
Publikováno v:
Relevé des maladies transmissibles au Canada. 49:143-149
Autor:
Makan Cheraghpour, Zahra Yari, Azita Hekmatdoost, Mehdi Hedayati, Seyede Marjan Mohaghegh, Zahra Naser-Nakhaee, Shahrzad Ommi, Elahe Karimi-Shahrbabak
Publikováno v:
Diabetology & Metabolic Syndrome
Diabetology & Metabolic Syndrome, Vol 13, Iss 1, Pp 1-11 (2021)
Diabetology & Metabolic Syndrome, Vol 13, Iss 1, Pp 1-11 (2021)
Background Regarding the increasing prevalence of cardiometabolic abnormalities, and its association with non-communicable chronic diseases, providing preventive and therapeutic strategies is a priority. A randomized placebo-controlled study was cond
Autor:
Zahra Yari, Shahrzad Ommi, Makan Cheraghpour, Mehdi Hedayati, Elahe Karimi-Shahrbabak, Seyed Moayed Alavian, Azita Hekmatdoost, Hossein Imani
Publikováno v:
Phytotherapy research : PTR. 33(8)
This study aimed to evaluate the effects of hesperidin on nonalcoholic fatty liver disease (NAFLD) characteristics. In this randomized, double-blind, controlled clinical trial, 50 NAFLD patients were supplemented with either 1-g hesperidin capsule or